The safer aspirin PA 325 is a patented formulation of 325mg of aspirin surrounded by a 20mg coating of an immediate release formulation of a proton pump inhibitor.
Each subject was treated with either once a day commercially available enteric coated aspirin 325mg or PA 325. The primary endpoint was gastrointestinal damage. The results were highly significant with many more in the enteric coated aspirin group having gastrointestinal damage than those in the PA 325.
Furthermore, no ulcers were seen in the PA group, while 20% of subjects in the enteric coated aspirin 325mg group developed a gastric ulcer during the study. This difference was also statistically significant.
“The data from this first clinical study with PA 325 is very encouraging,” stated Dr John Plachetka, president and CEO.